Nuevocor logo

Nuevocor

Pioneering novel therapies for untreatable cardiac diseases

29 employees · est. 2021 · Singapore, Singapore

VS
Phlox Therapeutics logo

Phlox Therapeutics

RNA's to rescue cardiomyopathies

7 employees · est. 2022 · Naarden, The Netherlands

Nuevocor is the older company (2021 vs 2022); Nuevocor is the larger of the two.

Side-by-Side Comparison

Nuevocor Phlox Therapeutics
Founded
2021 older 2022
Headquarters
Singapore, Singapore Naarden, The Netherlands
Employees
29 larger 7
Industry
Biopharma, Biotechnology, Pharmaceutical Biotechnology, Health and Wellness
Funding Stage
Series B Not tracked yet
Total Funding
$80.60M Not tracked yet
Funding Rounds
3 Not tracked yet
Services
Development of novel therapies for cardiomyopathies, Genetic medicine research and development, Mechanobiology-centered treatment approaches Not tracked yet
Target Customers
Patients with untreatable cardiomyopathies, Healthcare providers specializing in cardiology, Research institutions focusing on cardiovascular diseases Not tracked yet
Taxonomy
Genetic Medicines, Cardiomyopathies, Gene Therapy, Cardiac Function Restoration, PrOSIA Mechanobiology Platform, Preclinical-stage, Biopharmaceutical Company, Genetic Cardiomyopathies, Novel Therapies, Cardiac Diseases, Disease Treatment Gene Therapy, Cardiomyopathies, RNA-based Strategies, Genetic Mutations, Pharmaceuticals, Innovation, Medical Research, Genomics
Website
nuevocor.com phloxtherapeutics.com
Nuevocor logo

About Nuevocor

Nuevocor, founded in 2021, is a pioneering company in the Biopharma, Biotechnology, and Pharmaceutical industries. With its headquarters nestled in Singapore and operational reach extending to the USA, Nuevocor is at the forefront of developing genetic medicines targeted at previously untreatable ge...

Phlox Therapeutics logo

About Phlox Therapeutics

Phlox Therapeutics is a biotechnology startup based in The Netherlands that was founded in 2022. The company's mission is encapsulated in its slogan, "RNA's to rescue cardiomyopathies," which reflects its focus on pioneering gene therapy to alleviate and cure cardiomyopathies. Phlox Therapeutics aim...

We will tell you when either one moves

BounceWatch watches Nuevocor and Phlox Therapeutics for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Nuevocor and Phlox Therapeutics — by email.

Frequently Asked Questions

Nuevocor — Pioneering novel therapies for untreatable cardiac diseases. Phlox Therapeutics — RNA's to rescue cardiomyopathies. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Nuevocor has raised $80.60M while Phlox Therapeutics has raised undisclosed funding.
Nuevocor and Phlox Therapeutics operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Nuevocor with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Nuevocor on 15 Jun 2026, and Phlox Therapeutics on 11 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes